Phase 1 Alzheimer's Disease Trial, Not Yet Recruiting (NCT07373067)

Phase 1 Alzheimer's Disease Trial, Not Yet Recruiting NCT07373067 Sponsor: Regeneration Biomedical, Inc. Condition: Alzheimer's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07373067 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Alzheimers Disease

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

The person must have already completed an earlier part of this research (a single-dose study called Protocol RB-ADSC-02).
The person, or someone legally authorised to decide on their behalf, must have signed a form agreeing to take part in this extension study.
The person must have a family member or carer who is able to watch out for any possible side effects.
That family member or carer must also meet separate eligibility requirements set by the trial for caregivers (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

People who had a serious or significant treatment-related safety event during the earlier study (Protocol RB-ADSC-02) may not be eligible.
People whom the lead trial doctor considers unsuitable for this extension study may not be eligible.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 10 August 2026

Contact this trial

Phone: 877-240-1660

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07373067

Sponsor: Regeneration Biomedical, Inc.

Phase: Phase 1

Status: Not Yet Recruiting

Condition: Alzheimer's Disease

Trial contact: 877-240-1660

More information: https://clinicaltrials.gov/study/NCT07373067

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who may be able to join

The person must have already completed an earlier part of this research (a single-dose study called Protocol RB-ADSC-02).
The person, or someone legally authorised to decide on their behalf, must have signed a form agreeing to take part in this extension study.
The person must have a family member or carer who is able to watch out for any possible side effects.
That family member or carer must also meet separate eligibility requirements set by the trial for caregivers (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

People who had a serious or significant treatment-related safety event during the earlier study (Protocol RB-ADSC-02) may not be eligible.
People whom the lead trial doctor considers unsuitable for this extension study may not be eligible.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 10 August 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Not Yet Recruiting

Phase

Phase 1

Sponsor

Regeneration Biomedical, Inc.

Registry

ClinicalTrials.gov

Start date

1 January 2026

Est. completion

1 January 2028

Primary endpoints

The safety of repeated RB-ADSC treatment in study participants with AD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov

Who may and may not be able to join

Who may be able to join

Who may not be able to join

Contact this trial

GP referral letter

Who may be able to join

Who may not be able to join

Trial details

Primary endpoints

Can't join this trial?

Expanded access pathways

Other trials for Alzheimer's Disease